Björses K, Holst J
Department of Vascular Diseases, Malmö University Hospital, Lund University, S-205 02 Malmö, Sweden.
Eur J Vasc Endovasc Surg. 2007 Mar;33(3):363-70. doi: 10.1016/j.ejvs.2006.10.011. Epub 2006 Nov 28.
To evaluate the effects of different local hemostatic agents in a new high flow vascular experimental bleeding model.
Bovine thrombin combined with collagen matrix (bTcM), microporous polysaccharide hemospheres (MPH), freeze-dried rFVIIa with and without the combination of MPH were compared to a control group (solely compression) in a randomized fashion (20 animals/group). Primary endpoint was hemostasis, and secondary endpoints were time to hemostasis, blood loss, and blood pressure at hemostasis.
The common carotid artery of heparinized rats was ligated proximally and transected. Compression was applied for one minute followed by application of the topical hemostatic agent. Compression was maintained for another two minutes followed by re-evaluation of hemostasis: if bleeding continued additional compression was applied and thereafter bleeding was checked every minute until hemostasis.
All animals in the bTcM group obtained hemostasis compared to 20% in the control group (p<0.0001). The combination of MPH and rFVIIa (70% hemostasis) also showed a significant hemostatic capacity compared to control group (p<0.001). None of the other active treatment groups differed compared to control group. Animals treated with bTcM had a significantly shorter time to hemostasis compared to animals in the other active treatment groups. No significant difference in blood loss and blood pressure at hemostasis was detected.
The most effective hemostatic agent was bTcM, followed by the combination of rFVIIa and MPH, while neither MPH nor rFVIIa alone displayed any hemostatic capacity compared to compression only.
在一种新型高流量血管实验性出血模型中评估不同局部止血剂的效果。
将牛凝血酶与胶原基质(bTcM)、微孔多糖微球(MPH)、添加和未添加MPH的冻干重组活化凝血因子VII(rFVIIa)与对照组(仅采用压迫止血)进行随机比较(每组20只动物)。主要终点是止血,次要终点是止血时间、失血量和止血时的血压。
将肝素化大鼠的颈总动脉在近心端结扎并横断。压迫止血1分钟,随后应用局部止血剂。再持续压迫2分钟,之后重新评估止血情况:如果仍有出血,则继续压迫,此后每分钟检查一次出血情况,直至止血。
bTcM组所有动物均实现止血,而对照组为20%(p<0.0001)。MPH与rFVIIa联合使用(止血率70%)与对照组相比也显示出显著的止血能力(p<0.001)。其他活性治疗组与对照组相比无差异。与其他活性治疗组的动物相比,接受bTcM治疗的动物止血时间明显更短。在失血量和止血时的血压方面未检测到显著差异。
最有效的止血剂是bTcM,其次是rFVIIa与MPH的联合使用,而单独使用MPH或rFVIIa与仅采用压迫止血相比均未显示出任何止血能力。